Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
      Description

      This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin MelanomaMET Fusion Gene PositiveNRAS wt AlleleNTRK1 Fusion PositiveNTRK2 Fusion PositiveNTRK3 Fusion PositiveRET Fusion PositiveROS1 Fusion PositiveStage III Cutaneous MelanomaStage IIIA Cutaneous MelanomaStage IIIB Cutaneous MelanomaStage IIIC Cutaneous MelanomaStage IV Cutaneous Melanoma
      Talk to us